Logo
x

Search

Subscribe Now

formycon

Formycon Reports the EC’s Approval of FYB203 (Biosimilar, Eylea) Under the Brand Names Ahzantive and Baiama

Formycon Reports the EC’s Approval of FYB203 (Biosimilar, Eylea) Under the Brand Names Ahzantive and Baiama

  • January 21, 2025
Formycon and Fresenius Kabi Report the MHRA’s Approval of Otulfi (Biosimilar, Stelara)

Formycon and Fresenius Kabi Report the MHRA’s Approval of Otulfi (Biosimilar, Stelara)

  • January 16, 2025
Formycon and Fresenius Kabi Reports the EC’s Approval of Otulfi (Biosimilar, Stelara) for Serious Inflammatory Diseases

Formycon and Fresenius Kabi Reports the EC’s Approval of Otulfi (Biosimilar, Stelara) for Serious Inflammatory Diseases

  • September 27, 2024
Formycon and Klinge Biopharma Reports the US FDA’s Approval of Ahzantive (Biosimilar, Eylea)

Formycon and Klinge Biopharma Reports the US FDA’s Approval of Ahzantive (Biosimilar, Eylea)

  • July 1, 2024
The EMA Accepts Formycon’s MAA for FYB203 to Treat Neovascular Age-Related Macular Degeneration (AMD)

The EMA Accepts Formycon’s MAA for FYB203 to Treat Neovascular Age-Related Macular Degeneration (AMD)

  • December 27, 2023
Formycon’s Ranopto Receives Health Canada’s Approval for the Treatment of Several Retinal Diseases

Formycon’s Ranopto Receives Health Canada’s Approval for the Treatment of Several Retinal Diseases

  • December 7, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.